Functionally, loss of S100A16 disrupted RNA Polymerase I activation and subsequent rRNA synthesis, reversed epithelial-to-mesenchymal transition, inhibited invasion, and reduced metastatic incidence in animal models of breast cancer. Here, S100A16 is linked to breast cancer.